Immunization is one of the highest impact and most cost effective methods of preventing infectious diseases, particularly in low and middle income countries with minimal healthcare facilities in remote locations. Many vaccines technologies that could aid improved safety, efficacy and delivery are in development, such as needle free administration, increasing the magnitude and prolonged existence of protective immune responses induced by vaccines at the same time as reducing the dose, and improved vaccine stabilization.
There is an unmet need to produce effective vaccines against a number of deadly infectious diseases such as AIDS, malaria and hepatitis C. Although, vaccines for Infectious diseases such as TB and influenza exist, but are only partially effective and need significant improvement to respond to the real public health needs
The application of modern biological technologies and advances in genomics has resulted in novel concepts like reverse vaccinology, DNA vaccines, recombinant subunit vaccines and non-replicating vectors, some of these concepts have already progressed to advanced clinical trials and new products such as the meningococcal and hepatitis B vaccine. Recently, cancer and certain autoimmune disorders have received attention as targets for both prophylactic and therapeutic vaccines.
The global vaccine market projected to rise to $43.5 billion by 2018, growing at a CAGR of 12.65%. Rapid advances in understanding of the immune system and desire of medical community to engineer both preventive and therapeutic vaccines for a wide spectrum of diseases are fueling changes in medicine and in the managed care industry.
The growth of global Vaccine market is partly fuelled scientific breakthroughs such as genome sequencing of infectious pathogens, refined understanding of the immune system and its mechanism of response, followed by significant influx of money from public funding bodies, private charity and commercial organizations. Safety, demonstration of sufficiently high efficacy and lack of a consistent evaluation/development pathway are major stumbling blocks for development of new vaccines.
The major players operating in the human vaccine technology market includes Aduro biotech (U.S.), Antigen Express, INC. (U.S.), Sanofi (France) Pfizer, INC. (U.S.), Glaxo Smithkline PLC (U.K.), Novartis AG (Switzerland), Merck & CO., INC. (U.S.).
Key Topics Covered:
1. Executive Summary
3. Market Analysis
4. Vaccine Technologies Market, by End-User
5. Vaccine Technologies Market, by Type
6. Vaccine Technologies Market, by Class
7. Vaccine Technology Market, by Disease Indication
8. Regional Market Analysis
9. Company Developments
10. Major Company Profiles
- Antigen Express, INC.
- Bavarian Nordic
- Glaxo Smithkline PLC
- Liquidia Technologies
- Merck & CO., INC.
- Novartis AG
- Pfizer, INC.
For more information visit http://www.researchandmarkets.com/research/fb37v4/human_vaccine
Media Contact: Laura Wood, +353-1-481-1716, firstname.lastname@example.org
SOURCE Research and Markets